Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BTAI - BioXcel Therapeutics, Inc.

IEX Last Trade
0.36
-0.031   -8.611%

Share volume: 908
Last Updated: Thu 26 Dec 2024 04:26:56 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 4.47%

PREVIOUS CLOSE
CHG
CHG%
$0.39
-0.03
-7.93%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
30%
Profitability 25%
Dept financing 22%
Liquidity 59%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.96%
1 Month
-25.30%
3 Months
-33.28%
6 Months
-70.25%
1 Year
-88.41%
2 Year
-98.40%
Key data
Stock price
$0.36
P/E Ratio 
-0.23
DAY RANGE
$0.36 - $0.39
EPS 
-$3.32
52 WEEK RANGE
$0.34 - $4.17
52 WEEK CHANGE
-$88.06
MARKET CAP 
25.057 M
YIELD 
N/A
SHARES OUTSTANDING 
40.744 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
0.84
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$941,053
AVERAGE 30 VOLUME 
$922,773
Company detail
CEO: Vimal D. Mehta
Region: US
Website: bioxceltherapeutics.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

BioXcel Therapeutics, Inc. uses artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Recent news